REUTERS - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.
- Teva to buy Allergan Plc's generic drugs unit for $40.5 billion
- Teva Pharmaceutical profit beats forecast, raises 2015 earnings estimate
- FDA okays first generic version of Teva's MS drug Copaxone
The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.
Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka.